E-drug: Re: Drug approval criteria (cont'd)
----------------------------------------------------------
In a couple of recent postings the subject of the Australian scheme for
re-imbursement of pharmaceutical products on cost-effectiveness grounds was
mentioned. The summary by Shu Li from Singapore posted on 15th April is
very accurate. The program is undergoing re-evaluation at the moment,
based on experience of detailed evaluation of more than 300 submissions
from the industry. Modifications to the existing guidelines will be
released later this year and more extensive modifications will be made next
year. In the meantime two manuscripts are in preparation and there is a
comprehensive Powerpoint presentation for a couple of conferences that are
taking place in the next month or so. If anyone is keen to get more detail
could they please contact me directly and I will forward copies of the
material when it is ready for public exposure.
David Henry
David Henry
Discipline of Clinical Pharmacology
School of Population Health Sciences
Faculty of Medicine and Health Sciences
The University of Newcastle
New South Wales
Australia
Phone +61 249 211856
Fax +61 249 602088
mddah@mail.newcastle.edu.au
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.